Xeloda Monitoring
Patients on capecitabine (Xeloda) require close clinical monitoring by an experienced oncology provider, with particular attention to hand-and-foot syndrome, gastrointestinal toxicity, renal function, hepatic function, and coagulation parameters if on anticoagulants. 1
Essential Monitoring Parameters
Clinical Monitoring
Hand-and-Foot Syndrome (Palmar-Plantar Erythrodysesthesia)
- Monitor for numbness, dysesthesia, tingling, erythema, or painful swelling of hands/feet at each visit 1
- Median time to onset: 79 days (range 11-360 days) 1
- Grade 2 (painful erythema affecting daily activities) or Grade 3 (moist desquamation, ulceration, severe pain preventing work): interrupt treatment until resolved to Grade 0-1 1
- Following Grade 3, reduce subsequent doses 1
Gastrointestinal Toxicity
- Assess for diarrhea and stomatitis at each visit
- Grade 3-4 diarrhea requires dose interruption and reduction 1
- Severe enterocolitis can occur and may require hospitalization 2
Cardiotoxicity
- Monitor for chest pain, dyspnea, or cardiac symptoms, especially in patients with prior coronary artery disease 1
- Capecitabine can cause myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, and cardiomyopathy 1
Laboratory Monitoring
Renal Function
- Monitor creatinine clearance (CrCl) before and during treatment 1, 3
- Patients with CrCl 30-50 mL/min require 75% dose reduction 3
- Capecitabine is contraindicated if CrCl <30 mL/min 1, 3
- Renal impairment increases systemic exposure to 5'-DFUR (23% increase) and FBAL (109% increase) for 50% reduction in CrCl 3
- Consider renography for early detection of nephrotoxicity, as BUN and creatinine may remain normal despite declining renal function 4
Hepatic Function
- Monitor bilirubin, alkaline phosphatase, and transaminases regularly 1
- Grade 3 hyperbilirubinemia (1.5-3× ULN) occurred in 15.2% and Grade 4 (>3× ULN) in 3.9% of patients 1
- Patients with hepatic metastases have higher rates of hyperbilirubinemia (22.8% vs 12.3%) 1
- Carefully monitor patients with mild-to-moderate hepatic dysfunction 1
Coagulation Parameters (Critical)
- Monitor INR or prothrombin time frequently in patients on warfarin or other coumarin-derivative anticoagulants 1
- Clinically significant increases in PT/INR can occur within several days to several months after starting capecitabine 1
- This interaction has resulted in bleeding and death 1
- Adjust anticoagulant dose accordingly 1
Hematologic Monitoring
- Monitor complete blood count for neutropenia, though less common than with IV 5-FU 5
Special Considerations
DPYD Deficiency Screening
- Consider pre-treatment DPYD genotyping, particularly in North American patients who may experience greater toxicity than European patients 6, 7
- DPYD variants occur in approximately 4.1% of patients 7
- Patients with DPYD variants have 2.3% treatment-related mortality vs 0.1% in those without variants 7
- Dose reductions of 25-50% recommended for intermediate metabolizers; avoid capecitabine in poor metabolizers 7
Therapeutic Drug Monitoring
- Consider therapeutic drug monitoring, especially after severe adverse events 2
- AUC of 5'-DFUR correlates with Grade 3-4 adverse events 3
Monitoring Frequency
- Baseline: CrCl, CBC, liver function tests, coagulation parameters (if on anticoagulants), DPYD genotyping (consider)
- During first cycle: Close monitoring for toxicity with dose adjustments as needed 1
- Ongoing: Clinical assessment at each visit (every 3 weeks for standard dosing), laboratory monitoring per institutional protocols
- INR monitoring: Frequently if on warfarin, especially within first month and after dose changes 1
Common Pitfalls
- North American patients require lower starting doses (850-1000 mg/m² vs 1250 mg/m²) due to increased toxicity risk 8, 6
- Patients with diminished CrCl require dose modification even if serum creatinine appears normal 6, 4
- Severe renal impairment patients (CrCl <30 mL/min) experienced 100% rate of Grade 3-4 adverse events in studies 3
- Never increase dose after reduction 1